Sep 24, 2021

New research detects early signs of Alzheimer’s with almost 100% accuracy

Mild cognitive impairment (MCI) is often an early sign of Alzheimer’s disease, and though it usually has no clear symptoms early on, it can sometimes be identified with brain scans – known as functional magnetic resonance imaging (FMRI) – even before symptoms appear.

However, identifying MCI with FMRI is both time consuming and expensive.

Now researchers have used deep learning technology – a type of artificial intelligence – that could potentially speed up the process, and they are able to detect MCI with better than 99% accuracy.

The research involved using a deep learning model to classify thousands of images of the brains of 138 subjects with various stages of MCI. The model was able to identify MCI accurately in more than 99% of cases.

Alzheimer’s is a debilitating, progressive disease that has no cure.

Approximately 24 million people currently have Alzheimer’s disease, and that number is expected to double every 20 years.

It’s widely accepted that early diagnosis means the patient is more likely to benefit from treatment.

The aim is for the algorithm to be developed into software that could analyse data from vulnerable groups, such as the over 65s, those with a history of brain injury or those with high blood pressure.

The software could be used to pick up anomalies that could enable earlier diagnoses of Alzheimer’s.

The researchers say the algorithm should not be relied upon alone for a diagnosis, but it can provide useful information quickly and affordably, meaning the patient can have a diagnosis and treatment more quickly.

“Of course, we don’t dare to suggest that a medical professional should ever rely on any algorithm 100%”, said Maskeliūnas.

“Think of a machine as a robot capable of doing the most tedious task of sorting the data and searching for features. 

“In this scenario, after the computer algorithm selects potentially affected cases, the specialist can look into them more closely, and at the end, everybody benefits as the diagnosis and the treatment reaches the patient much faster.”

While there is still no cure for Alzheimer’s, this research is another promising step on the road to better treatments.

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement
Advertisement
Advertisement

“A slow and painful journey”: Why did it take over 20 years to approve the new Alzheimer’s drug?

There’s considerable support from patient groups and many doctors and scientists for the early approval of this drug, but there are some who don’t agree with this decision. Read More

New Initiative Lowering Antipsychotic Medication In Aged Care Facilities

  It is scary enough to cope with the change that dementia and ageing brings without having to journey through the complex side-effects of anti-psychotic medication. From falls, strokes, sleep disturbances and agitation, psychotropic agents have great impacts on all, especially seniors. Pioneered by a team from the Wicking Dementia Research and Education Centre and... Read More

Retirement Living Industry Taking Big Steps Towards Improving Standards

The retirement living industry is currently on the verge of one of the most significant and positive steps-forward that the sector has ever seen thanks to the new Retirement Living Code of Conduct.  The new code, that will take full effect from 1 January 2020, was finalised after an extensive 12-month development process including consultation... Read More
Advertisement
Exit mobile version